首页 胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual)

胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual)

举报
开通vip

胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual)胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual) 胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual) Novorapid 30 flexpen - only to find the "charge", deal with it Drug name: novorapid 30 flexpen Insulin Aspart 30 Injection Novorapid 30 FlexPen Description: novorapid 30...

胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual)
胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual) 胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual) Novorapid 30 flexpen - only to find the "charge", deal with it Drug name: novorapid 30 flexpen Insulin Aspart 30 Injection Novorapid 30 FlexPen Description: novorapid 30 flexpen (for the treatment of diabetes mellitus) can better simulate the physiological insulin secretion, improve postprandial glucose control, less severe and nocturnal hypoglycemia, and the meal immediately before injection, greatly increase the treatment compliance of patients. Novorapid 30 flexpen: Category: Imported Drugs [name of drug] Commodity name: novorapid 30 flexpen Drug name (medium): Insulin Aspart 30 Injection Chinese Pinyin: Mendongyidaosu 30 Zhusheye English Name: Insulin Aspart 30 Injection Dosage form: injection [main ingredient] insulin aspart (using biotechnology to replace the proline of human insulin amino acid chain B28). [character] this product is clear and colorless aqueous solution of insulin aspart. [pharmacological toxicity] hypoglycemic effects of insulin aspart insulin aspart is through a combination of molecular and muscle and adipose cells on insulin receptor, promote glucose uptake, while inhibiting glycogen release to achieve. Human insulin aspart core amino acid chain B28 in the proline was replaced by aspartic acid, so human soluble insulin in the tendency to form six dimer is reduced in insulin aspart in. Thus, subcutaneous absorption is faster than soluble human insulin. [pharmacokinetics] human soluble insulin aspart lead is rapid onset, lower the blood glucose concentration decreased. The duration of the injection was short after subcutaneous injection. The average time for insulin to reach the highest blood concentration was 50% of soluble human insulin. The peak time of type 1 diabetic patients is about 40 minutes after subcutaneous injection. About 4-5 hours after injection, the concentration returned to base. This product absorbs very quickly. But there are differences between groups the highest blood concentration, stressed the importance of novorapid refill individualized treatment. [indications] used in the treatment of diabetes mellitus [usage] this product is faster than the soluble human insulin, and has a shorter duration of action. It is usually due to rapid onset, so it is generally necessary to be injected immediately before meals. Take the medicine immediately after meals, if necessary. The dosage should be individualized and decided by the doctor according to the patient's condition. But it should be used in combination with medium or long-acting insulin, at least once a day. The insulin requirement is usually 0.5-1.0U per kilogram body weight. Among them, 2/3 dosage is prandial insulin, another 1/3 dosage is base insulin. The improvement of metabolic control in diabetic patients can effectively delay the occurrence and progression of late complications. Therefore, improvements in metabolic control, including glucose testing, are recommended. After subcutaneous injection, the abdominal wall, thigh, deltoid region and gluteal region can be selected, or continuous infusion in the abdominal wall. The injection position shall be rotated in the same area. After subcutaneous injection, it takes effect within 10-20 minutes, so it is necessary to eat carbohydrate containing foods within 10 minutes after injection. The maximal effect time was 1-3 hours after injection, and the hypoglycemic effect lasted for 3-5 hours. Do not use this medicine if the solution is no longer transparent or colorless. To prevent cross infection, this product is for personal use only. Before use, please check the integrity of the product (for example: no cracks), if the cartridge has been damaged, or rubber piston issued a white bar code band, please do not use. Dial the needle after each injection. If the needle is not removed after injection, the change of temperature will cause the liquid to leak out of the needle. Don't refill the product. To determine the concentration of insulin before injection and type the correct, and in accordance with the guidelines for the use of insulin injection system of Novo Nordisk, careful operation. This product is used for subcutaneous injection. If insulin is injected from the abdominal wall, it works faster. The injection site can be the abdomen, thighs, upper arms, or hips. The injection site should be rotated in the same area. Treatment of this product and other insulin refill as when two novo insulin syringes were used, each for different types of insulin injection syringe. [adverse reactions] hypoglycemia is the most frequent adverse event in insulin treatment. Symptoms of hypoglycemia often occur suddenly. Treatment with insulin may lead to edema and abnormal visual function, but these symptoms are transient. Local anaphylaxis may also occur during the course of insulin treatment (redness, edema, and itching) at the injection site. But usually for a short while, continuing treatment can disappear. Systemic anaphylaxis rarely occurs, but can be life-threatening. If the injection site is not rotated, it is possible to develop fat malnutrition at the injection site. [hypoglycemia] hypoglycemia, allergic to insulin aspart or other components of the preparation. [note] inadequate dosage or treatment interruption may lead to hyperglycemia and ketoacidosis, especially in type 1 diabetes mellitus (insulin-dependent diabetes mellitus). The first symptoms of hyperglycemia usually occur over hours or days. It includes nausea, vomiting, lethargy, flushing of the skin, dryness, dry lips, increased frequency of urination, thirst, loss of appetite, and breath with acetone. Untreated hyperglycemia events are likely to lead to death. Injection time novorapid should be closely linked with the meal time, which is close to the pre meal. It works quickly, so it is necessary to consider whether the patient's comorbidities and the combination of drugs delay the absorption of food. A combination of diseases, especially infections, often increases the amount of insulin used. Liver or kidney damage can reduce the amount of insulin used in patients. When patients switch to other types or brands of insulin, strict medical monitoring should be maintained. Changes in insulin concentration, brand, type, species (animal, insulin, human insulin, human insulin analog) and / or manufacturing processes will lead to changes in dosage. Patients from the other application of insulin aspart after use may increase the number of daily injections or change the dose. If this adjustment is necessary, it will take place during the first or first few weeks or months. After the patient's glycemic control has been improved, for example, the initial symptoms of hypoglycemia can change after intensive insulin therapy, and attention should be given to the patient. Only in children compared with soluble insulin aspart using rapid onset under more favorable circumstances. For example, when the injection time is related to the meal time. If hypoglycemia occurs, the rapid onset of pharmacodynamics of the insulin analog results in hypoglycemia occurring earlier after insulin aspart injection than in soluble human insulin. If a large amount of exercise meal or not included in the plan of physical exercise may lead to hypoglycemia. Hypoglycemia may damage the patient's attention and responsiveness. As a result, there may be danger in the patient's particularly important activities (such as driving a car or operating machinery). Patients should be advised to guard against hypoglycemia during driving, especially in patients with reduced or decreased signs of hypoglycemia and frequent hypoglycemia. In this case, the patient should be allowed to continue driving. [pregnant and lactating women] there is no systematic study of pregnant women. It is recommended that women with diabetes, pregnancy, and pregnancy should be monitored throughout pregnancy until the end of pregnancy. In early pregnancy, the amount of insulin usually decreases and increases gradually after middle and late stages. No restrictions on the use of this product in lactating women. Breastfeeding mothers should be insulin does not cause harm to infants. But the dosage of insulin aspart may need to be adjusted. [children] use this product only when compared with soluble insulin, which is more rapidly effective. [elderly patients] good [drug interaction] [drug overdose] would be hypoglycemia symptoms, including cold sweat, pale, fatigue, nervousness or anxiety, tremor, abnormal fatigue or weakness, mental disorders, difficulty concentrating, abnormal sleepiness, hunger, visual changes, headache, nausea and palpitation. Severe hypoglycemia can cause coma and / or convulsions, temporary or permanent brain damage or even death. Mild hypoglycemia can be treated with oral glucose or sugar. Therefore recommends that diabetics carry sugar or sugary foods such as biscuits. The patient was unconscious when severe hypoglycemia occurred, Glucagon can be administered by intramuscular or subcutaneous injection of trained persons or by intravenous administration of glucose by medical personnel. If the patient does not respond to glucagon within 10-15 minutes, glucose should also be given intravenously. [specifications] 100 units per milliliter, 3 ml per bottle (special charge). [storage] unused products should be refrigerated at 2-8 degrees Celsius (not too close to cold ice chamber), not frozen. [validity] 24 months [import drug registration number] S20040058 [approval number of imported drugs separately] J20050018 [manufacturer] Denmark, Novo Nordisk Novorapid 30 flexpen price: RMB 108 Objectives: adherence to 4567 (fasting 4~5, 2 h after meal, 6~7), control 5678 (fasting <5.6, 2 hours after meal, <7.8).
本文档为【胰岛素诺和锐30r的使用说明书(Insulin aspart 30R manual)】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
下载需要: 免费 已有0 人下载
最新资料
资料动态
专题动态
is_477730
暂无简介~
格式:doc
大小:30KB
软件:Word
页数:7
分类:生活休闲
上传时间:2018-01-24
浏览量:69